Beam Therapeutics annual cash and equivalents
2019
2020
2021
2022
2023
2024
2025
Beam Therapeutics Cash & Equivalents Growth & History (BEAM)
Beam Therapeutics's cash and equivalents was $294.9M for fiscal 2025.
View full Beam Therapeutics company overviewBeam Therapeutics annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $294.9M | $13.0M | +4.60% |
| 2024 | 2024-12-31 | $282.0M | −$153.9M | −35.31% |
| 2023 | 2023-12-31 | $435.9M | $203.1M | +87.27% |
| 2022 | 2022-12-31 | $232.8M | −$327.2M | −58.43% |
| 2021 | 2021-12-31 | $560.0M | $397.8M | +245.31% |
| 2020 | 2020-12-31 | $162.2M | $125.0M | +335.70% |
| 2019 | 2019-12-31 | $37.2M | — | — |
Beam Therapeutics quarterly cash and equivalents
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $219.8M | −$62.3M | −22.08% |
| Q1 2026 | 2026-03-31 | $288.3M | −$239.6M | −45.39% |
| Q4 2025 | 2025-12-31 | $294.9M | $13.0M | +4.60% |
| Q3 2025 | 2025-09-30 | $268.0M | $37.8M | +16.40% |
| Q2 2025 | 2025-06-30 | $282.1M | −$10.6M | −3.63% |
| Q1 2025 | 2025-03-31 | $527.9M | $240.1M | +83.40% |
| Q4 2024 | 2024-12-31 | $282.0M | −$153.9M | −35.31% |
| Q3 2024 | 2024-09-30 | $230.2M | $61.2M | +36.18% |
| Q2 2024 | 2024-06-30 | $292.8M | $67.2M | +29.80% |
| Q1 2024 | 2024-03-31 | $287.8M | $38.1M | +15.24% |
| Q4 2023 | 2023-12-31 | $435.9M | $203.1M | +87.27% |
| Q3 2023 | 2023-09-30 | $169.0M | $12.5M | +8.01% |
| Q2 2023 | 2023-06-30 | $225.5M | −$40.1M | −15.09% |
| Q1 2023 | 2023-03-31 | $249.8M | −$47.0M | −15.85% |
| Q4 2022 | 2022-12-31 | $232.8M | −$327.2M | −58.43% |
| Q3 2022 | 2022-09-30 | $156.5M | −$455.5M | −74.43% |
| Q2 2022 | 2022-06-30 | $265.6M | $53.6M | +25.29% |
| Q1 2022 | 2022-03-31 | $296.8M | $199.6M | +205.24% |
| Q4 2021 | 2021-12-31 | $560.0M | $397.8M | +245.31% |
| Q3 2021 | 2021-09-30 | $612.0M | $474.1M | +343.81% |
| Q2 2021 | 2021-06-30 | $212.0M | $86.7M | +69.20% |
| Q1 2021 | 2021-03-31 | $97.2M | −$28.8M | −22.86% |
| Q4 2020 | 2020-12-31 | $162.2M | $125.0M | +335.70% |
| Q3 2020 | 2020-09-30 | $137.9M | — | — |
| Q2 2020 | 2020-06-30 | $125.3M | — | — |
| Q1 2020 | 2020-03-31 | $126.0M | — | — |
| Q4 2019 | 2019-12-31 | $37.2M | — | — |
Beam Therapeutics cash and equivalents trends
Over the last five fiscal years, Beam Therapeutics's cash and equivalents increased from $162.2M to $294.9M, a change of $132.8M. The latest reported quarter, Q2 2026, shows $219.8M.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Beam Therapeutics source filings ↗Community posts
Beam reports durable protein correction with experimental AATD therapy
Beam Therapeutics ($BEAM) presented updated Phase 1/2 results for BEAM-302, its experimental gene-editing treatment for alpha-1 antitrypsin deficiency. The presentation covered 29 patients given a single dose, with follow-up extending to 18 ...